Rosiglitazone and type 2 diabetes mellitus [15]

Lancet

Volumn 357, Issue 9266, 2001, Pages 1451-

  Bragg, T ^a  

^a Novo Nordisk Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035810545     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04611-0     Document Type: Letter

References (2)

1. DR Matthews Guidance on rosiglitazone for type 2 diabetes Lancet 357 2001 481
2. Technology Appraisal Guidance, No 9 August 2000 NHS National Institute for Clinical Excellence London